Author:
Jayan Athira,Mammen Andrew L.,Suarez-Almazor Maria E.
Funder
National Cancer Institute
Pfizer
Eli Lilly and Company
Syneos Health
Reference50 articles.
1. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis;Hamada;Front Times,2021
2. Rheumatic diseases and syndromes induced by cancer immunotherapy;Mammen,2021
3. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature;Guerra;Autoimmun Rev,2023
4. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors;Aldrich;Arthritis Rheumatol,2021
5. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities;Allenbach;Autoimmun Rev,2020